Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

alanphillips/E+ via Getty Images The performance of Pacific Biosciences (NASDAQ:PACB) ("PacBio") is all too familiar to readers who've followed this stock for a long time, as once again the stock is trading below $2 on fears that the company simply won't be able to stay in the game long enough to benefit from future growth in long-read sequencing (as well as skepticism that long-read sequencing will grow enough to support a$1B+ revenue base). Down more than 80% since my last update, underperforming other s ...